

## Special Issue

# Thyroid Cancer: From Biology to Therapeutic Opportunities

### Message from the Guest Editors

Thyroid cancer (TC) is the most common endocrine neoplasia. In recent years, TC studies have dramatically improved the understanding of the molecular mechanisms leading to the initiation and progression of TC.

The promising results of the immune checkpoint inhibitors used in patients with TC highlight the critical role of the immune system in TC advancement. Furthermore, the recent achievements in molecular biology represent the starting point for new genetic and epigenetic research aiming to delve into thyroid carcinogenesis and, consequently, help to achieve a better outcome in advanced TC cases.

This Special Issue aims to present the latest research in the molecular landscape, which may contribute to decoding pathogenesis, refining diagnosis, prognosis, and therapy of TC. You are welcome to submit for publication systematic or narrative reviews, original research, animal or cell culture models that provide new insights into the molecular mechanisms and may have an impact on TC management.

---

### Guest Editors

Dr. Cristina Alina Silaghi

Prof. Dr. Carmen Emanuela Georgescu

Dr. Horațiu Silaghi

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/138756](https://mdpi.com/si/138756)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).